Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience
BackgroundDedifferentiated liposarcoma (DDLPS) is one of the most common types of soft tissue sarcoma (STS) characterized by liposarcomatous differentiation and a predilection for the retroperitoneum. Despite the growing number of histology-specific immune checkpoint blockade (ICB) trials in STS, it...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567736/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850142815766446080 |
|---|---|
| author | Madeline B. Torres Madeline B. Torres Cheuk Hong Leung Marianne Zoghbi Rossana Lazcano Davis Ingram Khalida Wani Emily Z. Keung M. Alejandra Zarzour Christopher P. Scally Kelly K. Hunt Anthony Conley Andrew J. Bishop B. Ashleigh Guadagnolo Ahsan Farooqi Devarati Mitra Alison K. Yoder Michael S. Nakazawa Dejka Araujo Andrew Livingston Ravin Ratan Shreyaskumar Patel Vinod Ravi Alexander J. Lazar Alexander J. Lazar Christina L. Roland Neeta Somaiah Elise F. Nassif Haddad Elise F. Nassif Haddad |
| author_facet | Madeline B. Torres Madeline B. Torres Cheuk Hong Leung Marianne Zoghbi Rossana Lazcano Davis Ingram Khalida Wani Emily Z. Keung M. Alejandra Zarzour Christopher P. Scally Kelly K. Hunt Anthony Conley Andrew J. Bishop B. Ashleigh Guadagnolo Ahsan Farooqi Devarati Mitra Alison K. Yoder Michael S. Nakazawa Dejka Araujo Andrew Livingston Ravin Ratan Shreyaskumar Patel Vinod Ravi Alexander J. Lazar Alexander J. Lazar Christina L. Roland Neeta Somaiah Elise F. Nassif Haddad Elise F. Nassif Haddad |
| author_sort | Madeline B. Torres |
| collection | DOAJ |
| description | BackgroundDedifferentiated liposarcoma (DDLPS) is one of the most common types of soft tissue sarcoma (STS) characterized by liposarcomatous differentiation and a predilection for the retroperitoneum. Despite the growing number of histology-specific immune checkpoint blockade (ICB) trials in STS, it is still difficult to identify the radiographic objective response rate (ORR) for DDLPS in the real world setting. This study aimed to evaluate the ORR and survival of patients with DDLPS treated with ICB at a single center.MethodsWe conducted a retrospective study of 31 patients with pathologically confirmed DDLPS treated with ICB at MD Anderson Cancer Center between 2018 and 2023. Patient demographics, disease characteristics, treatment history, and response to ICB were analyzed. Immunohistochemical analysis was performed on tumor samples to assess immune-related markers.ResultsORR by RECIST 1.1 was 3.2% (n=1/31). Among all patients (n=31), 6% achieved partial radiographic response, while 39% had stable disease, and 55% showed progressive disease. Median progression-free survival (PFS) was 3.5 (95%CI:1.9, 4.7) months, and overall survival (OS) after ICB initiation was 19.7 (95%CI: 8.8, not reached) months. Patients without prior systemic therapy demonstrated better OS (p=0.004). Immunohistochemistry revealed no relationship between pre- or post-ICB expression of CD8, CD20, CD21 and PDL-1 and response.ConclusionWhile the response to ICB in DDLPS remains limited, specific immune markers may influence treatment outcomes. CD20/21 post-ICB appear more important for prognosis. Further research is warranted to identify predictive factors for ICB efficacy in DDLPS. |
| format | Article |
| id | doaj-art-2aeb74ef38cb4842bef698ed2bb59db3 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-2aeb74ef38cb4842bef698ed2bb59db32025-08-20T02:28:55ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-04-011610.3389/fimmu.2025.15677361567736Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experienceMadeline B. Torres0Madeline B. Torres1Cheuk Hong Leung2Marianne Zoghbi3Rossana Lazcano4Davis Ingram5Khalida Wani6Emily Z. Keung7M. Alejandra Zarzour8Christopher P. Scally9Kelly K. Hunt10Anthony Conley11Andrew J. Bishop12B. Ashleigh Guadagnolo13Ahsan Farooqi14Devarati Mitra15Alison K. Yoder16Michael S. Nakazawa17Dejka Araujo18Andrew Livingston19Ravin Ratan20Shreyaskumar Patel21Vinod Ravi22Alexander J. Lazar23Alexander J. Lazar24Christina L. Roland25Neeta Somaiah26Elise F. Nassif Haddad27Elise F. Nassif Haddad28Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Surgery, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, United StatesDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesBackgroundDedifferentiated liposarcoma (DDLPS) is one of the most common types of soft tissue sarcoma (STS) characterized by liposarcomatous differentiation and a predilection for the retroperitoneum. Despite the growing number of histology-specific immune checkpoint blockade (ICB) trials in STS, it is still difficult to identify the radiographic objective response rate (ORR) for DDLPS in the real world setting. This study aimed to evaluate the ORR and survival of patients with DDLPS treated with ICB at a single center.MethodsWe conducted a retrospective study of 31 patients with pathologically confirmed DDLPS treated with ICB at MD Anderson Cancer Center between 2018 and 2023. Patient demographics, disease characteristics, treatment history, and response to ICB were analyzed. Immunohistochemical analysis was performed on tumor samples to assess immune-related markers.ResultsORR by RECIST 1.1 was 3.2% (n=1/31). Among all patients (n=31), 6% achieved partial radiographic response, while 39% had stable disease, and 55% showed progressive disease. Median progression-free survival (PFS) was 3.5 (95%CI:1.9, 4.7) months, and overall survival (OS) after ICB initiation was 19.7 (95%CI: 8.8, not reached) months. Patients without prior systemic therapy demonstrated better OS (p=0.004). Immunohistochemistry revealed no relationship between pre- or post-ICB expression of CD8, CD20, CD21 and PDL-1 and response.ConclusionWhile the response to ICB in DDLPS remains limited, specific immune markers may influence treatment outcomes. CD20/21 post-ICB appear more important for prognosis. Further research is warranted to identify predictive factors for ICB efficacy in DDLPS.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567736/fullsarcomadedifferentiated liposarcomaAnti-PD1immunotherapyimmune-checkpoint inhibitorssurvival |
| spellingShingle | Madeline B. Torres Madeline B. Torres Cheuk Hong Leung Marianne Zoghbi Rossana Lazcano Davis Ingram Khalida Wani Emily Z. Keung M. Alejandra Zarzour Christopher P. Scally Kelly K. Hunt Anthony Conley Andrew J. Bishop B. Ashleigh Guadagnolo Ahsan Farooqi Devarati Mitra Alison K. Yoder Michael S. Nakazawa Dejka Araujo Andrew Livingston Ravin Ratan Shreyaskumar Patel Vinod Ravi Alexander J. Lazar Alexander J. Lazar Christina L. Roland Neeta Somaiah Elise F. Nassif Haddad Elise F. Nassif Haddad Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience Frontiers in Immunology sarcoma dedifferentiated liposarcoma Anti-PD1 immunotherapy immune-checkpoint inhibitors survival |
| title | Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience |
| title_full | Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience |
| title_fullStr | Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience |
| title_full_unstemmed | Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience |
| title_short | Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience |
| title_sort | dedifferentiated liposarcomas treated with immune checkpoint blockade the md anderson experience |
| topic | sarcoma dedifferentiated liposarcoma Anti-PD1 immunotherapy immune-checkpoint inhibitors survival |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567736/full |
| work_keys_str_mv | AT madelinebtorres dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT madelinebtorres dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT cheukhongleung dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT mariannezoghbi dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT rossanalazcano dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT davisingram dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT khalidawani dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT emilyzkeung dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT malejandrazarzour dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT christopherpscally dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT kellykhunt dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT anthonyconley dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT andrewjbishop dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT bashleighguadagnolo dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT ahsanfarooqi dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT devaratimitra dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT alisonkyoder dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT michaelsnakazawa dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT dejkaaraujo dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT andrewlivingston dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT ravinratan dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT shreyaskumarpatel dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT vinodravi dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT alexanderjlazar dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT alexanderjlazar dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT christinalroland dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT neetasomaiah dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT elisefnassifhaddad dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience AT elisefnassifhaddad dedifferentiatedliposarcomastreatedwithimmunecheckpointblockadethemdandersonexperience |